

# A systematic review of hepatitis C virus epidemiology in

Liver International

31, 30-60

DOI: [10.1111/j.1478-3231.2011.02539.x](https://doi.org/10.1111/j.1478-3231.2011.02539.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Model Systems for Hepatitis C Research: The Cup Half Empty?. <i>Gastroenterology</i> , 2011, 141, 806-809.	0.6	5
2	Prevalence and risk factors of HCV infection in Poland. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1213-1217.	0.8	49
3	The global health burden of hepatitis C virus infection. <i>Liver International</i> , 2011, 31, 1-3.	1.9	121
4	Hepatitis C infection in Italian psoriatic patients: prevalence and correlation with patient age and psoriasis severity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1581-1582.	1.3	9
5	Hepatitis C Virus Infection Trends in Italy. <i>Hepatitis Monthly</i> , 2012, 12, 46-47.	0.1	3
6	Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373.	1.4	117
7	Evolving Epidemiology of Hepatitis C Virus in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S3-S9.	2.9	179
8	The burden of viral hepatitis C in Europe. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 869-877.	0.8	32
9	IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 817-823.	0.8	4
10	Transfusion transmission of HCV, a long but successful road map to safety. <i>Antiviral Therapy</i> , 2012, 17, 1423-1429.	0.6	28
12	Update on alisporivir in treatment of viral hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 375-382.	1.9	44
13	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521.	1.5	13
14	Peripheral blood cytopenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. <i>Liver International</i> , 2012, 32, 1113-1119.	1.9	27
16	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
17	Public health issues of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 371-380.	1.0	30
18	Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region. <i>BMC Infectious Diseases</i> , 2012, 12, S4.	1.3	13
19	High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. <i>PLoS ONE</i> , 2012, 7, e41206.	1.1	43
20	A Gaussia Luciferase Cell-Based System to Assess the Infection of Cell Culture- and Serum-Derived Hepatitis C Virus. <i>PLoS ONE</i> , 2012, 7, e53254.	1.1	7

#	ARTICLE	IF	CITATIONS
21	Viral infections: A tale of two genomes. <i>NursePrescribing</i> , 2012, 10, 551-555.	0.1	0
22	Management of rheumatic disease with comorbid HBV or HCV infection. <i>Nature Reviews Rheumatology</i> , 2012, 8, 348-357.	3.5	67
23	Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, S10-S15.	2.9	263
24	What's new in HCV genotype 2 treatment. <i>Liver International</i> , 2012, 32, 135-140.	1.9	14
25	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-8.	1.0	44
26	The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1209-1220.	1.9	7
27	Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. <i>Hepatology</i> , 2012, 55, 742-748.	3.6	318
28	Urban legends series: lichen planus. <i>Oral Diseases</i> , 2013, 19, 128-143.	1.5	65
29	Epidemiology and natural history of HCV infection. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 553-562.	8.2	833
30	Primary liver cancer incidence and survival in ethnic groups in England, 2001-2007. <i>Cancer Epidemiology</i> , 2013, 37, 34-38.	0.8	6
31	It gives me a sense of belonging: Providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. <i>International Journal of Drug Policy</i> , 2013, 24, 550-557.	1.6	22
32	Update on the Treatment of Patients With Non-Genotype 1 Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1294-1300.	2.9	5
33	Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. <i>Infection, Genetics and Evolution</i> , 2013, 17, 223-230.	1.0	22
34	Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete. <i>European Journal of Internal Medicine</i> , 2013, 24, 839-845.	1.0	9
35	Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475.	1.0	30
37	Development of Innovative and Versatile Polythiol Probes for Use on ELOSA or Electrochemical Biosensors: Application in Hepatitis C Virus Genotyping. <i>Analytical Chemistry</i> , 2013, 85, 9204-9212.	3.2	19
38	In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. <i>Antiviral Research</i> , 2013, 100, 439-445.	1.9	21
39	Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. <i>Journal of Viral Hepatitis</i> , 2013, 20, 669-677.	1.0	60

#	ARTICLE	IF	CITATIONS
40	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. <i>Current Hepatitis Reports</i> , 2013, 12, 261-268.	0.3	0
41	Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 150-156.	0.8	13
42	Chronic hepatitis C in Italy: The vanishing of the first and most consistent epidemic wave. <i>Digestive and Liver Disease</i> , 2013, 45, 369-370.	0.4	11
44	Chronic HCV infection is a risk factor of ischemic stroke. <i>Atherosclerosis</i> , 2013, 231, 22-26.	0.4	80
45	How did chronic hepatitis C impact costs related to hospital health care in France in 2009?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 365-372.	0.7	7
46	Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. <i>Journal of Clinical Virology</i> , 2013, 57, 263-266.	1.6	15
48	Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons. <i>Gastroenterology</i> , 2013, 144, 59-61.e6.	0.6	35
49	Effect of peginterferon alfa-2a (40<sc>KD</sc>) on cytochrome <sc>P</sc>450 isoenzyme activity. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 497-506.	1.1	22
50	How to optimize HCV therapy in genotype 2 patients. <i>Liver International</i> , 2013, 33, 35-40.	1.9	14
51	Hepatitis C virus vaccines – Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	1.3	34
52	Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 69.	0.2	21
53	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.	1.0	34
54	Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 295-297.	1.4	2
55	Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 504-508.	0.6	14
56	The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. <i>Nature Reviews Microbiology</i> , 2013, 11, 482-496.	13.6	336
57	Raising public awareness of hepatitis B and C through a testing road show. <i>British Journal of Nursing</i> , 2013, 22, 1308-1312.	0.3	3
58	Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4. <i>Hepatitis Monthly</i> , 2013, 13, e13678.	0.1	15
59	Distribution of Hepatitis C Virus Genotypes among Azerbaijani Patients in Capital City of Iran-Tehran. <i>Hepatitis Monthly</i> , 2013, 13, e13699.	0.1	21

#	ARTICLE	IF	CITATIONS
60	Integrating Phylodynamics and Epidemiology to Estimate Transmission Diversity in Viral Epidemics. <i>PLoS Computational Biology</i> , 2013, 9, e1002876.	1.5	57
61	Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5037-5044.	1.4	20
62	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	1.9	81
63	Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. <i>Liver International</i> , 2013, 33, 727-738.	1.9	32
64	Randomized Study of Asunaprevir plus Pegylated Interferon- $\alpha$ and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44
65	Hepatitis C in prisoners and non-prisoners in Colatina, Espírito Santo, Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2013, 49, 737-744.	1.2	9
66	Hepatitis C Virus Infection in Canada's First Nations People: A Growing Problem. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2013, 27, 335-335.	1.8	4
67	The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e101554.	1.1	362
68	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	1.1	15
69	Hepatitis C Worldwide and in Brazil: Silent Epidemic? Data on Disease including Incidence, Transmission, Prevention, and Treatment. <i>Scientific World Journal</i> , The, 2014, 2014, 1-10.	0.8	25
70	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. <i>World Journal of Gastroenterology</i> , 2014, 20, 9633.	1.4	135
71	Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa. <i>Systematic Reviews</i> , 2014, 3, 146.	2.5	24
72	Eltrombopag in patients with chronic hepatitis C and thrombocytopenia. <i>Future Virology</i> , 2014, 9, 9-20.	0.9	0
73	Oral manifestations of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 7534.	1.4	58
74	Epidemiology of hepatitis C in Europe. <i>Digestive and Liver Disease</i> , 2014, 46, S158-S164.	0.4	70
75	How to Interpret Borderline HCV Antibody Test Results: A Comparative Study Investigating Four Different Anti-HCV Assays. <i>Viral Immunology</i> , 2014, 27, 7-13.	0.6	7
76	Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. <i>Liver International</i> , 2014, 34, e308-16.	1.9	4
77	Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. <i>Journal of Epidemiology and Community Health</i> , 2014, 68, 1182-1188.	2.0	60

#	ARTICLE	IF	CITATIONS
78	A pill for <scp>HCV</scp> â€“ myth or foreseeable future?. Liver International, 2014, 34, 6-11.	1.9	20
79	Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon± and ribavirin in chronic hepatitis C virus patients. Liver International, 2014, 34, 551-557.	1.9	13
80	Daclatasvir for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology and Hepatology, 2014, 8, 725-738.	1.4	7
81	Robust and Persistent Replication of the Genotype 6a Hepatitis C Virus Replicon in Cell Culture. Antimicrobial Agents and Chemotherapy, 2014, 58, 2638-2646.	1.4	29
82	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Medical Research Methodology, 2014, 14, 39.	1.4	2
83	No strategy to meet the HCV epidemic. BMC Infectious Diseases, 2014, 14, S2.	1.3	6
84	Diagnostic accuracy evaluation of the ImmunoFlow HCV rapid immunochromatographic test for the detection of hepatitis C antibodies. Journal of Virological Methods, 2014, 204, 6-10.	1.0	16
85	Impact of New Hepatitis C Treatments in Different Regions of the World. Gastroenterology, 2014, 146, 1145-1150.e4.	0.6	48
86	Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?. BMC Public Health, 2014, 14, 3.	1.2	51
88	Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Alimentary Pharmacology and Therapeutics, 2014, 39, 137-147.	1.9	74
89	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	1.0	372
90	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in selected countries. Journal of Viral Hepatitis, 2014, 21, 5-33.	1.0	211
91	The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis. Journal of Clinical Virology, 2014, 60, 301-304.	1.6	29
92	How to optimize current treatment of genotype 2 hepatitis C virus infection. Liver International, 2014, 34, 13-17.	1.9	5
93	Trends in Substance Abuse and Infectious Disease over 20 Years in a Large Methadone Maintenance Treatment (MMT) Clinic in Israel. Substance Abuse, 2014, 35, 226-229.	1.1	6
94	IFNL cytokines do not modulate human or murine NK cell functions. Human Immunology, 2014, 75, 996-1000.	1.2	22
95	Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 2014, 61, S45-S57.	1.8	1,560
96	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet, The, 2014, 384, 1597-1605.	6.3	316

#	ARTICLE	IF	CITATIONS
97	HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infectious Diseases, 2014, 14, 222.	1.3	28
98	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	13.9	1,065
99	EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology, 2014, 60, 392-420.	1.8	739
100	Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. Autoimmunity Reviews, 2014, 13, 609-614.	2.5	37
101	Interferon-free hepatitis C treatment: one pill to fit all?. Lancet, The, 2014, 383, 491-492.	6.3	7
102	Health care-associated hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 17265.	1.4	39
103	Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction, 2015, 110, 1287-1300.	1.7	22
104	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	1.0	109
105	Seroprevalencia de hepatitis C en usuarios de unidades de medicina familiar en QuerĂ©taro, MĂ©xico. AtenciĂ³n Familiar, 2015, 22, 2-6.	0.0	2
106	Viral hepatitis in hemodialysis: An update. Journal of Translational Internal Medicine, 2015, 3, 93-105.	1.0	45
107	Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). Antiviral Therapy, 2016, 21, 195-205.	0.6	18
108	The epidemiology of hepatitis C virus in Afghanistan: systematic review and meta-analysis. International Journal of Infectious Diseases, 2015, 40, 54-63.	1.5	33
109	Haplotype analysis finds linkage disequilibrium in the IL-12 gene in patients with HCV. Journal of Medical Virology, 2015, 87, 1207-1217.	2.5	2
110	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology, 2015, 62, 1013-1023.	3.6	46
111	Hepatitis C virus genotype 4 in England: Diversity and demographic associations. Journal of Medical Virology, 2015, 87, 417-423.	2.5	3
112	Recommendations for treatment of hepatitis C. Polish Group of HCV Experts â€“ 2015. Clinical and Experimental Hepatology, 2015, 3, 97-104.	0.6	4
113	Cure of Hepatitis C. Acta Medica Portuguesa, 2015, 28, 10.	0.2	0
114	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 2015, 10, e0125214.	1.1	25

#	ARTICLE	IF	CITATIONS
115	The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0135281.	1.1	48
116	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS ONE, 2015, 10, e0145622.	1.1	2
117	Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. PLoS ONE, 2015, 10, e0143492.	1.1	0
118	Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology, 2015, 14, 642-651.	0.6	17
119	Hepatitis C virus, pregnancy and postnatal care. Gastrointestinal Nursing, 2015, 13, 26-32.	0.0	0
120	Gene Therapy for Hepatitis C Virus Infection. , 2015, , 191-226.		0
121	Altered effector functions of NK cells in chronic hepatitis C are associated with <i>IFNL3</i> polymorphism. Journal of Leukocyte Biology, 2015, 98, 283-294.	1.5	11
122	Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. Journal of Infection, 2015, 70, 197-205.	1.7	35
123	Hepatitis C. Lancet, The, 2015, 385, 1124-1135.	6.3	424
124	Historical epidemiology of hepatitis C virus ( <i>HCV</i> ) in select countries – volume 2. Journal of Viral Hepatitis, 2015, 22, 6-25.	1.0	92
125	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver International, 2015, 35, 1845-1852.	1.9	25
126	The present and future disease burden of hepatitis <i>C</i> virus ( <i>HCV</i> ) infections with today's treatment paradigm – volume 2. Journal of Viral Hepatitis, 2015, 22, 26-45.	1.0	117
127	Health state utilities associated with attributes of treatments for hepatitis C. European Journal of Health Economics, 2015, 16, 1005-1018.	1.4	35
128	Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?. European Journal of Health Economics, 2015, 16, 341-345.	1.4	9
129	Liver transplantation in the Nordic countries – An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982–2013. Scandinavian Journal of Gastroenterology, 2015, 50, 797-808.	0.6	70
130	Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection, 2015, 21, 1020-1026.	2.8	156
131	Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. Journal of Comparative Effectiveness Research, 2015, 4, 593-605.	0.6	4
132	Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. Journal of Medical Economics, 2015, 18, 678-690.	1.0	21



#	ARTICLE	IF	CITATIONS
133	A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries. PLoS Medicine, 2015, 12, e1001795.	3.9	32
134	Functionally conserved architecture of hepatitis C virus RNA genomes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3692-3697.	3.3	117
135	Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. Digestive and Liver Disease, 2015, 47, 351-355.	0.4	8
136	Hepatitis C Virus. Gastroenterology Clinics of North America, 2015, 44, 807-824.	1.0	12
137	Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. Journal of Viral Hepatitis, 2015, 22, 409-415.	1.0	26
138	Enhanced surveillance of hepatitis C in the EU , 2006 – 2012. Journal of Viral Hepatitis, 2015, 22, 590-595.	1.0	7
139	Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach. BMC Infectious Diseases, 2015, 15, 297.	1.3	21
140	The safety of daclatasvir for the treatment of hepatitis C. Expert Opinion on Drug Safety, 2015, 14, 1787-1797.	1.0	3
141	Epidemiology of Hepatitis C Virus. Gastroenterology Clinics of North America, 2015, 44, 699-716.	1.0	30
142	Barriers to HCV treatment in the era of triple therapy: a prospective multicentred study in clinical practice. Liver International, 2015, 35, 401-408.	1.9	16
143	Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon $\alpha$ plus ribavirin in chronic hepatitis C. Digestive and Liver Disease, 2015, 47, 151-156.	0.4	4
144	Hepatitis C virus genotype 3: a genotype that is not "easy-to-treat". Expert Review of Gastroenterology and Hepatology, 2015, 9, 375-385.	1.4	15
145	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956.	6.1	101
146	HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatology International, 2015, 9, 52-57.	1.9	9
147	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepatic Medicine: Evidence and Research, 2016, Volume 8, 75-80.	0.9	7
148	Prevalence of HCV genotypes in Poland – the EpiTer study. Clinical and Experimental Hepatology, 2016, 4, 144-148.	0.6	18
149	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in Pharmacology, 2016, 7, 197.	1.6	26
150	Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. European Journal of Gastroenterology and Hepatology, 2016, 28, 640-644.	0.8	20

#	ARTICLE	IF	CITATIONS
151	The role of living context in prescription opioid injection and the associated risk of hepatitis C infection. <i>Addiction</i> , 2016, 111, 1985-1996.	1.7	11
152	Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (<sc>CH</sc>â€œ) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 217-226.	1.0	45
153	The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. <i>Liver International</i> , 2016, 36, 971-976.	1.9	30
154	Literature review of the distribution of hepatitis C virus genotypes across Europe. <i>Journal of Medical Virology</i> , 2016, 88, 2157-2169.	2.5	23
155	Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. <i>Journal of Medical Virology</i> , 2016, 88, 1044-1050.	2.5	14
156	Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resourceâ€œconstrained settings. <i>Tropical Medicine and International Health</i> , 2016, 21, 603-609.	1.0	20
157	Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. <i>SpringerPlus</i> , 2016, 5, 1557.	1.2	29
158	Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. <i>Infectious Agents and Cancer</i> , 2016, 11, 53.	1.2	63
159	Hepatitis por el virus C. <i>Medicine</i> , 2016, 12, 484-493.	0.0	0
160	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016, 81, 82-89.	1.6	60
161	Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and meta-analysis of prevalence. <i>International Journal of Infectious Diseases</i> , 2016, 46, 116-125.	1.5	55
162	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2016, 80, 1-7.	1.6	13
163	HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. <i>Infection, Genetics and Evolution</i> , 2016, 45, 415-419.	1.0	3
164	Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. <i>Journal of Viral Hepatitis</i> , 2016, 23, 479-486.	1.0	35
165	Potential market size and impact of hepatitis C treatment in lowâ€œand middleâ€œincome countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 522-534.	1.0	15
166	Review article: treatment as prevention â€œ targeting people who inject drugs as a pathway towards hepatitis C eradication. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 145-156.	1.9	11
167	Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. <i>World Journal of Gastroenterology</i> , 2016, 22, 7824.	1.4	621
168	Diagnosis of hepatitis C virus infection in pregnant women in the healthcare system in Poland. <i>Medicine (United States)</i> , 2016, 95, e4331.	0.4	5

#	ARTICLE	IF	CITATIONS
169	A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. <i>BMC Infectious Diseases</i> , 2016, 16, 565.	1.3	12
170	High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1246-1252.	0.8	11
171	Efficacy of Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Genotype-1 and -3 HCV Infection: Results from a Russian Phase IIIb Study. <i>Antiviral Therapy</i> , 2016, 21, 671-678.	0.6	16
172	Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 527-543.	1.0	18
173	High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening. <i>Infection</i> , 2016, 44, 85-91.	2.3	11
174	Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. <i>Hepatology</i> , 2016, 63, 1090-1101.	3.6	81
175	Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2016, 23, 244-255.	1.0	78
176	Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1-12.	1.0	24
177	Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. <i>Journal of Viral Hepatitis</i> , 2016, 23, 697-707.	1.0	3
178	Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv218.	0.4	26
179	Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir. <i>Clinical Pharmacokinetics</i> , 2016, 55, 605-613.	1.6	44
180	Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 13-20.	1.4	10
181	Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. <i>Journal of Hepatology</i> , 2016, 64, 292-300.	1.8	38
182	A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 16-41.	2.9	56
183	Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. <i>Journal of Medical Virology</i> , 2017, 89, 1304-1308.	2.5	0
184	Eliminación de la hepatitis C en España: adaptación de un modelo matemático de salud pública partiendo del plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina Clínica</i> , 2017, 148, 277-282.	0.3	24
185	Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the Tj ETQq0 0.0 rgBT /Overlock 10	1.0	28
186	Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	28

#	ARTICLE	IF	CITATIONS
187	HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients. <i>Antiviral Therapy</i> , 2017, 22, 431-441.	0.6	11
188	Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. <i>Journal of Viral Hepatitis</i> , 2017, 24, 944-954.	1.0	12
189	What weighs more—low compliance with self-deferral or minor medical procedures? Explaining the high rate of hepatitis C virus window-period donations in Poland. <i>Transfusion</i> , 2017, 57, 1998-2006.	0.8	8
190	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.78431 4 rgBT6/Overlook		
191	Time trends of cause-specific mortality among resettlers in Germany, 1990 through 2009. <i>European Journal of Epidemiology</i> , 2017, 32, 289-298.	2.5	13
192	Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. <i>Journal of Hepatology</i> , 2017, 66, 711-717.	1.8	22
193	Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands. <i>International Journal of Drug Policy</i> , 2017, 47, 117-125.	1.6	20
194	Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. <i>Epidemiology and Infection</i> , 2017, 145, 2873-2885.	1.0	99
195	Syphilis, hepatitis C and HIV in Eastern Europe. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 93-100.	1.3	13
196	Prevalence of hepatitis C virus infection and its correlates in a rural area of southwestern China: a community-based cross-sectional study. <i>BMJ Open</i> , 2017, 7, e015717.	0.8	2
197	Exploring the acceptability of a "limited patient consent procedure"™ for a proposed blood-borne virus screening programme: a Delphi consensus building technique. <i>BMJ Open</i> , 2017, 7, e015373.	0.8	13
199	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 61-68.	0.6	12
200	Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 45-52.	1.4	20
201	Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. <i>Current Medical Research and Opinion</i> , 2017, 33, 11-21.	0.9	15
202	No suitable precise or optimized epidemiologic search filters were available for bibliographic databases. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 112-118.	2.4	10
203	Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-11.	0.8	44
204	Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. <i>PLoS ONE</i> , 2017, 12, e0187893.	1.1	8
205	Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. <i>BMC Infectious Diseases</i> , 2017, 17, 624.	1.3	9

#	ARTICLE	IF	CITATIONS
206	Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C. <i>Israel Journal of Health Policy Research</i> , 2017, 6, 46.	1.4	3
207	Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 67-73.	0.9	9
208	Intravenous drug use “an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. <i>Archives of Medical Science</i> , 2017, 3, 652-658.	0.4	13
209	Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil - the Brazilian Global Burden of Disease Study. <i>Annals of Hepatology</i> , 2017, 16, 893-900.	0.6	14
210	Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. <i>European Journal of Internal Medicine</i> , 2018, 53, 79-84.	1.0	69
211	Dissecting the decline of hepatitis C in first-time donors in England and Wales. <i>Vox Sanguinis</i> , 2018, 113, 329-338.	0.7	6
212	Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. <i>Scientific Reports</i> , 2018, 8, 1661.	1.6	134
213	The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. <i>Scientific Reports</i> , 2018, 8, 150.	1.6	87
214	Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries. <i>BMC Infectious Diseases</i> , 2018, 18, 42.	1.3	43
215	Community-based screening of hepatitis C with a one-step <i>RNA</i> detection algorithm from dried blood spots: Analysis of key populations in Barcelona, Spain. <i>Journal of Viral Hepatitis</i> , 2018, 25, 236-244.	1.0	29
216	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 85-91.	1.3	6
218	Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014–2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1347-1353.	0.6	4
219	A Population-Based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. <i>Medicina (Lithuania)</i> , 2018, 54, 9.	0.8	4
220	The removal of DAA restrictions in Europe “One step closer to eliminating HCV as a major public health threat. <i>Journal of Hepatology</i> , 2018, 69, 1188-1196.	1.8	78
221	Epidemiology and Modes of Transmission of HCV in Developing Countries. , 2018, , 13-22.		1
222	Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada. <i>Canadian Liver Journal</i> , 2018, 1, 34-50.	0.3	15
223	Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. <i>BMC Infectious Diseases</i> , 2018, 18, 79.	1.3	83
224	The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. <i>Royal Society Open Science</i> , 2018, 5, 180257.	1.1	83

#	ARTICLE	IF	CITATIONS
225	HCV elimination among people who inject drugs. Modelling pre- and post-â€œWHO elimination era. PLoS ONE, 2018, 13, e0202109.	1.1	24
226	Dependence of intravoxel incoherent motion diffusion MR threshold <i>b</i>-value selection for separating perfusion and diffusion compartments and liver fibrosis diagnostic performance. Acta Radiologica, 2019, 60, 3-12.	0.5	19
227	Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. BMC Infectious Diseases, 2019, 19, 688.	1.3	16
228	Perspectives of hepatitis C virus (HCV) elimination in Poland. Clinical and Experimental Hepatology, 2019, 5, 210-214.	0.6	6
229	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver International, 2019, 39, 1818-1836.	1.9	44
230	Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon, 2019, 5, e02249.	1.4	16
231	Global Epidemiology of Chronic Hepatitis C Virus Infection. , 2019, , 1-24.		0
232	Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area. Journal of Hospital Infection, 2019, 102, 359-368.	1.4	15
233	Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. European Journal of Health Economics, 2019, 20, 857-867.	1.4	8
234	Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups. Journal of Clinical Epidemiology, 2020, 119, 26-35.	2.4	0
235	Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health, 2020, 20, 1345.	1.2	7
236	Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Infection, Genetics and Evolution, 2020, 86, 104606.	1.0	1
237	Using population-level incidence of hepatitis C virus and immigration status for data-driven screening policies: a case study in Israel. Journal of Public Health, 2022, 44, 2-9.	1.0	0
238	Hepatitis C in Israeli prisons: status report. Harm Reduction Journal, 2020, 17, 79.	1.3	0
239	Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data. Virology Journal, 2020, 17, 36.	1.4	10
240	Prescription and efficacy of daclatasvir and sofosbuvir Â± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The COMPASS-EU cohort study. Cogent Medicine, 2020, 7, .	0.7	3
241	Frequency of Hepatitis C Virus Genotypes in Patients Who Had Hepatocellular Carcinoma in Gastroenterological Hospitals of Tabriz. Journal of Gastrointestinal Cancer, 2021, 52, 145-149.	0.6	0
242	Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness. Gastroenterology Research, 2021, 14, 31-40.	0.4	0

#	ARTICLE	IF	CITATIONS
243	Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital. Romanian Journal of Laboratory Medicine, 2021, 29, 93-103.	0.1	0
244	Current Management of Patients with HCV Genotype 2. , 2021, , 83-95.		0
245	Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt. PLoS ONE, 2021, 16, e0246836.	1.1	14
246	Percutaneous microwave ablation applications for liver tumors: recommendations for COVID-19 patients. Heliyon, 2021, 7, e06454.	1.4	6
247	Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver International, 2021, 41, 1775-1788.	1.9	9
248	Solubility Behavior of Boc-L-proline in 14 Pure Solvents from 283.15 to 323.15 K. Journal of Chemical & Engineering Data, 2021, 66, 2812-2821.	1.0	7
249	A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes and New Infections, 2021, 42, 100895.	0.8	9
250	A systematic review of outbreaks of bloodborne infections (hepatitis B and C, HIV) transmitted from patient to patient in healthcare settings. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 98, 319-330.	0.3	2
251	Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infectious Diseases, 2021, 21, 667.	1.3	6
252	Determinants of HCV-related complications in Italian primary care patients. Liver International, 2021, 41, 2857-2865.	1.9	7
253	One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection. Annals of Hepatology, 2022, 27, 100542.	0.6	2
254	Hepatitis C virus subtype 3a was introduced in the USSR in the early 1980s. Journal of General Virology, 2017, 98, 2079-2087.	1.3	3
255	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. PLoS ONE, 2013, 8, e55285.	1.1	91
256	Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of Their Diagnosis: A Patient Survey. PLoS ONE, 2014, 9, e86070.	1.1	22
257	The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses. PLoS ONE, 2015, 10, e0121873.	1.1	48
258	Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C. PLoS ONE, 2015, 10, e0126984.	1.1	36
259	The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants—An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots. PLoS ONE, 2015, 10, e0135656.	1.1	47
260	The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0141715.	1.1	74

#	ARTICLE	IF	CITATIONS
261	Hepatitis C Virus Epidemiology in Djibouti, Somalia, Sudan, and Yemen: Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0149966.	1.1	46
262	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS ONE, 2016, 11, e0155464.	1.1	9
263	Prevalence of hepatitis C virus in adult population in the Czech Republic – time for birth cohort screening. PLoS ONE, 2017, 12, e0175525.	1.1	22
264	Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS ONE, 2017, 12, e0178398.	1.1	29
265	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections – A Scandinavian real-life study. PLoS ONE, 2017, 12, e0179764.	1.1	28
266	Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon $\alpha$ -2a and Ribavirin for Chronic Hepatitis C. ACG Case Reports Journal, 2015, 2, 247-249.	0.2	4
267	Benefits of Curing Hepatitis C Infection. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 85-90.	0.5	15
269	Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials. Revista Espanola De Enfermedades Digestivas, 2015, 107, 591-7.	0.1	5
270	Distribution of hepatitis C virus genotypes and subtypes in Croatia: 2008-2015. Central European Journal of Public Health, 2018, 26, 159-163.	0.4	5
271	Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b. Archives of Biological Sciences, 2014, 66, 193-201.	0.2	1
272	Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Eurosurveillance, 2017, 22, .	3.9	8
273	Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. Eurosurveillance, 2019, 24, .	3.9	8
274	Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. Journal of Health Economics and Outcomes Research, 2019, 6, 1-19.	0.6	2
275	Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World Journal of Gastroenterology, 2014, 20, 10984.	1.4	20
276	Epidemiology of hepatitis C in Croatia in the European context. World Journal of Gastroenterology, 2015, 21, 9476.	1.4	12
277	Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World Journal of Gastroenterology, 2015, 21, 10811.	1.4	41
278	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2763.	1.4	6
279	Seroprevalence rates of transfusion-transmitted infections among blood donors in Jordan. Journal of Infection in Developing Countries, 2016, 10, 377-383.	0.5	14



#	ARTICLE	IF	CITATIONS
280	Hépatite C chez les usagers de drogues par voie veineuse; exploration des barrières et des facilitateurs pour l'accès aux soins et services. <i>Sante Publique</i> , 2016, Vol. 28, 363-374.	0.0	3
281	Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 531.	0.3	9
282	Hepatitis C virus genotypes in north eastern Algeria: A retrospective study. <i>World Journal of Hepatology</i> , 2013, 5, 393.	0.8	22
283	Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. <i>World Journal of Hepatology</i> , 2015, 7, 703.	0.8	5
284	Hepatitis B and C in Switzerland – healthcare provider initiated testing for chronic hepatitis B and C infection. <i>Swiss Medical Weekly</i> , 2013, 143, w13793.	0.8	23
285	Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. <i>Gut and Liver</i> , 2020, 14, 207-217.	1.4	18
286	Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. <i>World Journal of Virology</i> , 2013, 2, 6.	1.3	19
287	Hepatitis C Virus Genotypes and Association With Viral Load in Yazd, Central Province of Iran. <i>Hepatitis Monthly</i> , 2014, 14, e11705.	0.1	19
288	Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland. <i>Hepatitis Monthly</i> , 2015, 15, e27740.	0.1	13
289	Hepatitis C Virus Infection Trends in Italy. <i>Hepatitis Monthly</i> , 2012, 12, 46-47.	0.1	1
290	The Epidemiological Patterns of Hepatitis C in Lithuania: Changes in Surveillance from 2005 to 2018. <i>Medicina (Lithuania)</i> , 2021, 57, 1120.	0.8	4
291	The acute hepatic flare in a patient with chronic hepatitis C infection receiving pegylated interferon alpha 2b and ribavirin. <i>Journal of Microbiology and Infectious Diseases</i> , 2012, 2, 121-123.	0.1	1
292	Therapie der chronischen Hepatitis C. <i>Pharma-Kritik (discontinued)</i> , 2012, 34, .	0.0	0
293	Hepatitis Viruses: Hepatitis C. , 2014, , 765-783.		0
294	Changing Epidemiology of Chronic Hepatitis C in Adana. <i>Viral Hepatitis Journal</i> , 2014, 20, 15-18.	0.1	2
295	Influence of GSTM1, GSTT1 and GSTP1 xenobiotic metabolism genes polymorphisms on treatment efficiency in patients with chronic hepatitis C. <i>Kazan Medical Journal</i> , 2014, 95, 202-208.	0.1	0
298	Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases. <i>Journal of Microbiology and Infectious Diseases</i> , 2016, 5, 151-155.	0.1	0
300	VIRAL HEPATITIS C: EVOLUTION OF THE EPIDEMIOLOGIC PROCESS, EVOLUTION OF THE VIRUS. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2016, 93, 102-112.	0.3	7

#	ARTICLE	IF	CITATIONS
301	Hepatitis C Virus Genotypes in Patients Referred to Educational Hospitals in Zahedan (2009 â€ 2013). International Journal of Infection, 2016, 3, .	0.4	0
302	Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavirin in patients with chronic genotype 1 hepatitis C. Klinicheskaia Meditsina, 2016, 94, 224-230.	0.2	1
303	Recurrent Incisional Hernia Associated with Interferon Treatment for Virus C Hepatitis: Case Report. Acta Marisiensis - Seria Medica, 2016, 62, 260-262.	0.3	0
304	Chronic Hepatitis C. In Clinical Practice, 2017, , 183-199.	0.1	1
306	Prognostic value of blood group specificity and IL-28B genotype for the assessment of liver fibrosis in patients with chronic genotype 1 hepatitis C, non-responders to the treatment with pegylated interferon 1±2 and ribavirin. Klinicheskaia Meditsina, 2017, 95, 847-854.	0.2	0
307	Emergency department targeted screening for hepatitis C does not improve linkage to care. World Journal of Gastroenterology, 2020, 26, 4878-4888.	1.4	5
308	Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children. Klinische Padiatrie, 2021, 233, 211-215.	0.2	2
309	Hepatitis C Virus Infection Trends in Italy. Hepatitis Monthly, 2012, 12, 46-47.	0.1	0
310	Hepatitis C virus infection trends in Italy. Hepatitis Monthly, 2012, 12, 46-7.	0.1	2
311	Surveillance system for hepatitis C infection: A practical approach. International Journal of Preventive Medicine, 2012, 3, S48-57.	0.2	2
312	Pretreatment serum interleukin-12 levels in predicting sustained virological response among hepatitis C patients following Pegylated Interferon-1±2 plus Ribavirin treatment. Annals of Gastroenterology, 2013, 26, 249-254.	0.4	2
313	Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 â€ Boston, MassachusettsSpecial Reporting on:â€ Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Networkâ€ Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Studyâ€ Efficacy and Safety of MK-5172 and Sofosbuvir in Gastroenterology and Hepatology, 2014, 61, 1111-1112.	0.2	20
314	Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China. International Journal of Clinical and Experimental Medicine, 2015, 8, 14871-84.	1.3	0
315	Distribution of the genotype of the Hepatitis C Virus in Cordoba-Spain. Revista Espanola De Quimioterapia, 2018, 31, 164-165.	0.5	1
316	Overview of blood-borne viral infections in hemodialysis patients: hepatitis B, hepatitis C, human immunodeficiency virus infections. Journal of Health Sciences and Medicine, 2022, 5, 195-200.	0.0	1
317	Predicting death or recurrence of portal hypertension symptoms after TIPS procedures. European Radiology, 2022, 32, 3346-3357.	2.3	9
319	Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study. Substance Abuse: Research and Treatment, 2022, 16, 117822182210958.	0.5	2
320	Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Frontiers in Microbiology, 2022, 13, .	1.5	5

#	ARTICLE	IF	CITATIONS
322	Lichen planus in Germany â€“ epidemiology, treatment, and comorbidity. A retrospective claims data analysis. JDDG - Journal of the German Society of Dermatology, 2022, 20, 1101-1110.	0.4	2
323	Lichen planus in Deutschland â€“ Epidemiologie, Behandlung und KomorbiditÃt. Eine retrospektive Krankenkassendatenanalyse. JDDG - Journal of the German Society of Dermatology, 2022, 20, 1101-1111.	0.4	0
324	Country versus pharmaceutical company interests for hepatitis C treatment. Health Care Management Science, 2022, 25, 725-749.	1.5	1
325	Analysis of Hepatitis C Virus Genotypes and RNA Quantitative Values in Cheonan, Republic of Korea from 2007 to 2016. Microbiology and Biotechnology Letters, 2022, 50, 422-429.	0.2	0
326	Clinical Trials and Regulatory considerations of Antiviral agents. , 2023, , 709-739.		0
327	Hepatitis C: epidemiology, natural history, and diagnosis. , 2023, , 229-250.		0
328	Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis. Scientific Reports, 2023, 13, .	1.6	7
329	Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen. Journal of Health Economics and Outcomes Research, 0, , 1-19.	0.6	0
330	Epidemiological situation on viral hepatitis Ð’ and Ð¡ among medical workers in the Voronezh region. Sanitarnyj VraÄ, 2023, , 134-145.	0.1	0